Benitec Biopharma Inc. (BNTC) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Benitec Biopharma Inc. (BNTC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

10.37

-0.02 (-0.19%)

At close: Jan 14, 2025, 3:59 PM

10.38

0.10%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	10.2
Market Cap	240.75M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.94
PE Ratio (ttm)	-3.53
Forward PE	n/a
Analyst	Buy

Ask	11.1
Volume	26,119
Avg. Volume (20D)	56,204
Open	10.31
Previous Close	10.39
Day's Range	10.20 - 10.64
52-Week Range	2.69 - 13.29
Beta	undefined

About BNTC

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company w...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 24, 2014

Employees 16

Stock Exchange NASDAQ

Ticker Symbol BNTC

Website https://benitec.com

Analyst Forecast

According to 6 analyst ratings, the average rating for BNTC stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 131.44% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

8 months ago · Source

-12.22%

Benitec Biopharma shares are trading lower after t... Unlock content with Pro Subscription

9 months ago · Source

+42.08%

Benitec Biopharma shares are trading higher. The company announced a $40 million oversubscribed private placement financing and reported interim clinical data for the first OPMD subject treated with BB-301 in its Phase 1b/2a study.

News

2 days ago · zacks.com

Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock

Benitec Biopharma (BNTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

3 weeks ago · zacks.com

Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

1 month ago · zacks.com

Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 113.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am...

1 month ago · zacks.com

Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

2 months ago · seekingalpha.com

Benitec Biopharma: OPMD Program Continues To Advance With Catalysts

Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026. BB-301 demonstrated significant improveme...